Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 547-556

  Calza, Leonardo ^a   Manfredi, Roberto ^a   Colangeli, Vincenzo ^a   Trapani, Fabio Filippo ^a   Salvadori, Caterina ^a   Magistrelli, Eleonora ^a   Danese, Ilaria ^a   Verucchi, Gabriella ^a   Serra, Carla ^a   Viale, Pierluigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; ROSUVASTATIN; TENOFOVIR; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY BIFURCATION; CAROTID ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMMON CAROTID ARTERY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; INTERNAL CAROTID ARTERY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 84874503638     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0015     Document Type: Article

References (44)

1. Friedl AC, Attenhofer Jost CH, Schalcher C, Amann FW, Flepp M, Jenni R, et al.: Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 2000;14:2790-2792.
2. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al.: Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118: e29-e35.
3. Calza L, Manfredi R, and Verucchi G: Myocardial infarction risk in HIV-infected patients: Epidemiology, pathogenesis, and clinical management. AIDS 2010;24:789-802.
4. Maggi P, Perilli F, Lillo A, Gargiulo M, Ferraro S, Grisorio B, et al.: Rapid progression of carotid lesions in HAART-treated HIV-1 patients. Atherosclerosis 2007;192:407-412.
5. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, et al.: Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008;196: 720-726.
6. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al.: Preclinical atherosclerosis due to HIV infection: Carotid intima-media thickness measurements from the FRAM study. AIDS 2009;23:1841-1849.
7. Calza L, Verucchi G, Pocaterra D, Pavoni M, Alfieri A, Cicognani A, et al.: Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. Int J STD AIDS 2009;20:683-689.
8. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al.: Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-1608.
9. Mercié P, Thiébaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Cipriano C, et al.: Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med 2005;6:380-387.
10. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al.: Carotid artery intima-media thickness and HIV infection: Traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;19:927-933.
11. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-Analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-1278.
12. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al.: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
13. Albert MA, Danielson E, Rifai N, Ridker PM, and the PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64-70.
14. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, et al.: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: Additional results from the STELLAR trial. Clin Ther 2004;26:1388-1399.
15. Peters SA, Palmer MK, Grobbee DE, Crouse III JR, O'Leary DH, Raichlen JS, et al.: C-reactive protein lowering with rosuvastatin in the METEOR study. J Int Med 2010;268: 155-161.
16. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, et al.: Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients. Circ J 2011;76:221-229.
17. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.: 2007 guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
19. European AIDS Clinical Society: Guidelines. Version 6.0.October 2011. Available online at www.europeanaids clinicalsociety.org.\
20. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. March 2012. Available online at www .aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL .pdf.
21. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al.: for the Rosuvastatin Investigators Group: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolaemia. Am Heart J 2002;144:1044-1051.
22. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al.: for the Rosuvastatin Investigators Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolaemia: A randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-1043.
23. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
24. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
25. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JP, et al.: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009;373:1175-1182.
26. Zhou Q and Liao JK: Pleiotropic effects of statins: Basic research and clinical perspectives. Circ J 2010;74:818-826.
27. Bu D, Griffin G, and Lichtman AH: Mechanisms for the antiinflammatory effects of statins. Curr Opin Lipidol 2011;22: 165-170.
28. van Wissen S, Smilde TJ, de Groot E, Hutten BA, Kastelein JJ, and Stalenhoef AF: The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. Eur J Cardiovasc Prev Rehabil 2003;10:451-455.
29. Amarenco P, Labreuche J, Lavallee P, and Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-Analysis. Stroke 2004;35: 2902-2909.
30. Kablak-Ziembicka A, Przewlocki T, Sokolowski A, Tracz W, and Podolec P: Carotid intima-media thickness, hs-CRP, and TNF-A are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis 2011;214:185-190.
31. Crouse III JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. JAMA 2007;297:1344-1353.
32. Riccioni G, Cipollone F, Santovito D, Scotti L, D'Orazio N, Mezzetti A, et al.: Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease. Expert Opin Pharmacother 2011;12:2599-2604.
33. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Philips PJ, et al.: Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy, adult male volunteers. Clin Ther 2003;25:2822-2835.
34. Williams D and Feely J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:434-470.
35. Calza L, Colangeli V, Manfredi R, Legnani G, Tampellini L, Pocaterra D, et al.: Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: A pilot study. AIDS 2005;19:1103-1105.
36. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, and Chiodo F: Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6:572-578.
37. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al.: Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: A randomized trial. AIDS 2010;24:77-83.
38. Gigue're JF and Tremblay MJ: Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-Associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004;78:2062-2065.
39. Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, et al.: Evaluation of the anti-HIV activity of statins. AIDS 2005;19:1697-1700.
40. Amet T, Nonaka M, Dewan MZ, Saitoh Y, Qi X, Ichinose S, et al.: Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect 2008;10:471-480.
41. Carr A: Statins as anti-inflammatory therapy in HIV disease? J Infect Dis 2011;203:751-752.
42. Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, and Costagliola D: High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 2011;25:1128-1131.
43. Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, et al.: High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011;203:756-764.
44. Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, et al.: Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-A in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials 2012;13:153-161.